BIOMAT Database Logo BIOMAT Database Logo

Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine. 1991

O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Stockholm, Sweden.

Patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who had p24 antigen despite treatment with zidovudine (AZT) for 4-28 months received 3 x 10(6) IU of native interferon-alpha (IFN-alpha) daily for 3 months. Infectious HIV was detected in the plasma of all patients, in most cases at high titers, before IFN-alpha treatment. There was no correlation between HIV titers and p24 antigen levels. Antiviral activity, as measured by significantly decreased levels of infectious virus or p24 antigen, was observed in six of eight completely treated but in only one of nine incompletely treated patients. After termination of IFN-alpha treatment, there was a significant rise of p24 antigen levels. During IFN treatment, absolute CD4 cell counts showed a tendency toward an increased rate of decline. The side effects were unexpectedly severe. Despite its anti-HIV effect in vivo, IFN-alpha in the dosages used does not seem to be a viable additional treatment for severely immunodeficient patients in ongoing AZT therapy.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014758 Viral Core Proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID. Core Proteins, Viral,Major Core Protein,Major Core Proteins, Viral,Adenovirus Core Protein VII,Core Protein V,Core Protein lambda 2,Influenza Virus Core Proteins,Major Core Protein lambda 1,Major Core Protein lambda-1,Major Core Protein sigma 2,Major Core Protein sigma-2,OVP 19,Oncornaviral Protein P19,P30 Core Proteins,Viral Protein P19,Virus Core Proteins,Core Protein, Major,Core Proteins, P30,Core Proteins, Virus,Protein P19, Oncornaviral,Protein P19, Viral,Protein, Major Core,Proteins, P30 Core,Proteins, Viral Core,Proteins, Virus Core
D014766 Viremia The presence of viruses in the blood. Viremias

Related Publications

O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
June 1994, The Journal of infectious diseases,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.
January 1994, International journal of clinical & laboratory research,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.
April 1993, The New England journal of medicine,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
May 1997, The New England journal of medicine,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
October 1990, Annals of internal medicine,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
July 1991, The Journal of infectious diseases,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
August 1993, Annals of neurology,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
January 1991, Disease markers,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection.
September 1996, The Journal of infectious diseases,
O Berglund, and K Engman, and A Ehrnst, and J Andersson, and K Lidman, and B Akerlund, and A Sönnerborg, and O Strannegård
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection.
December 1990, Genitourinary medicine,
Copied contents to your clipboard!